March 19, 2020 – With the integration of technology into all facets of everyday life, the life sciences and healthcare industry is hardly alone in facing technology-related issues. These take on increased importance when they impact health, disease diagnosis, treatment and, ultimately, human longevity. Having the right leaders in place to sort through these complex challenges, say recruiters serving the sector, is critical — especially those with vision and transformational skills.
Recently, life sciences-focused executive search firm Coulter Partners has placed Philip Lambert as chief scientific officer of NASDAQ-traded CENTOGENE in Cambridge, MA. Managing partner Kay Wardle led the assignment.
CENTOGENE is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies,
“We are extremely pleased to have Philip Lambert join CENTOGENE’s executive leadership team, and the extensive experience and knowledge in the rare disease field he adds to the company,” said Daniela Osterholz, head of human resources at CENTOGENE. “Philip’s appointment and the further profiling of the leadership team marks a significant advancement to the company’s pursuit to shorten the diagnostic odyssey and create treatment solutions for patients and their families. I would like to thank the team at Coulter Partners for their outstanding professional support in achieving this high caliber appointment.”
With more than two decades of experience in the global drug discovery and pre-clinical development sectors, Dr. Lambert will have the overall responsibility of driving scientific programs to align with the needs of pharmaceutical partners.
Dr. Lambert joins CENTOGENE from Life Biosciences, a global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He served as senior vice president of discovery and labs as well as chief operating officer of two subsidiary companies, Selphagy Therapeutics and Spotlight Biosciences.
Prior to that, Dr. Lambert was scientific partner and head of discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms. He also co-founded VivoPath, a preclinical screening company, offering clients discovery and development services for proof-of-concept testing. He holds a doctorate in neuropharmacology from Imperial College – University of London and a BSc in pharmacology from the University of Liverpool.
Tapping Outside Talent for Life Science and Healthcare
For these top 50 executive recruiters working in the life science and healthcare sectors, the last decade has been one of transformation. Pressure on pricing, regulatory changes, emerging innovations, growth, and an uncertain political environment have all helped shape a new field of play.
|Top 50 Ranking|
CENTOGENE, founded in 2006, has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.1 billion weighted data points from about 465,000 patients representing over 120 different countries.
Life Sciences Specialists
Coulter Partners is a senior-level executive search boutique focused exclusively on identifying global life sciences leaders and board directors. The firm serves clients in the pharmaceuticals, biotechnology, medical devices, diagnostics, CRO and services sectors. Coulter operates overseas offices in the U.K., Germany, Switzerland and Denmark. In the U.S., the firm has offices in Cambridge, MA; Princeton, NJ; Pittsburgh, PA; Los Angeles; and Short Hills, NJ.
Dr. Wardle has over 20 years of life science search experience and extensive R&D expertise. She has taken a lead on business development and delivery since joining Coulter Partners in 2013. Dr. Wardle has a strong focus on scientific and medical roles within R&D, spanning discovery, preclinical and clinical development, regulatory, product development, CMC and related disciplines. She has also placed C-suite, board and senior-level executives globally, working with both emerging and established organizations in the pharmaceutical, biotechnology and contract research sectors.
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media